Literature DB >> 17109104

Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation.

Eva Angenete1, Marcus Langenskiöld, Peter Falk, Marie-Louise Ivarsson.   

Abstract

BACKGROUND: In rectal cancer treatment, preoperative radiotherapy has led to reduction of local recurrence, but it is associated with morbidity and increased risk for secondary tumours. Matrix metalloproteinases (MMPs) are associated with tumour progression through tissue remodeling. The aim of this study was to investigate tissue remodeling after preoperative radiotherapy and to explore possible correlations with clinical outcome.
MATERIALS AND METHODS: Ninety-one patients scheduled for rectal cancer surgery were included; 49% received preoperative radiotherapy three-field treatment, 5 x 5 Gy. Blood samples and biopsies from tumour and adjacent mucosa were taken during surgery. Biopsies and plasma were assayed with ELISA for MMP-1, MMP-2 and MMP-9. Clinical outcome was reviewed focusing on infections, perineal healing, fistula formation, anastomotic dehiscence, small bowel obstruction, local recurrence and distant metastases.
RESULTS: Compared to non-irradiated mucosa, MMP-2 (p < 0.0001), MMP-1 (p = 0.03) and MMP-9 (p = 0.04) were significantly higher in irradiated normal mucosa. Tumour tissue had higher levels of MMP-2 if irradiated (p < 0.0001). A correlation between MMP-2 levels and wound infection (p = 0.02) as well as fistula formation (p = 0.04) was found. MMP-1 in mucosa (p = 0.02) and tumour (p = 0.04) were higher in patients developing distant metastases. Plasma levels were not influenced by irradiation, but MMP-2 was higher in patients who were later developing distant metastases (p = 0.007).
CONCLUSIONS: Extracellular matrix remodeling after radiotherapy seems to be correlated to postoperative morbidity; MMP-2 is associated with both wound infections and fistula formation. High levels of MMP-1 in tumour and mucosa as well as MMP-2 in plasma may be correlated to risk of developing distant metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109104     DOI: 10.1007/s00384-006-0225-3

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  39 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

4.  Clinical effects of preoperative radiation therapy on anorectal function after proctectomy and colonic J-pouch-anal anastomosis.

Authors:  Nidal Dehni; Deborah A McNamara; Rodulfo D Schlegel; Marguerite Guiguet; Emmanuel Tiret; Rolland Parc
Journal:  Dis Colon Rectum       Date:  2002-12       Impact factor: 4.585

5.  Changes of the extracellular matrix as a risk factor for anastomotic leakage after large bowel surgery.

Authors:  Michael Stumpf; Uwe Klinge; Arnulf Wilms; Robert Zabrocki; Rafael Rosch; Karsten Junge; Carsten Krones; Volker Schumpelick
Journal:  Surgery       Date:  2005-02       Impact factor: 3.982

6.  Etiology of small bowel obstruction.

Authors:  G Miller; J Boman; I Shrier; P H Gordon
Journal:  Am J Surg       Date:  2000-07       Impact factor: 2.565

7.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

Authors:  T Kirkegaard; A Hansen; E Bruun; J Brynskov
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

Review 9.  Late effects of radiation therapy on the gastrointestinal tract.

Authors:  L R Coia; R J Myerson; J E Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

10.  Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer.

Authors:  A Kumar; H M Collins; J H Scholefield; S A Watson
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  9 in total

1.  Anti-inflammatory and Anti-apoptotic Effect of Valproic Acid and Doxycycline Independent from MMP Inhibition in Early Radiation Damage.

Authors:  Ferda Hoşgörler; Didem Keleş; Serpil Tanrıverdi-Akhisaroğlu; Şeniz İnanç; Mustafa Akhisaroğlu; Ülker Cankurt; Zekiye Aydoğdu; Ahmet Deniz Uçar; Oğuz Çetinayak; Gülgün Oktay; Sevil Gönenç Arda
Journal:  Balkan Med J       Date:  2016-09-01       Impact factor: 2.021

2.  Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo.

Authors:  Romany L Stansborough; Noor Al-Dasooqi; Emma H Bateman; Joanne M Bowen; Dorothy M K Keefe; Richard M Logan; Ann S J Yeoh; Eric E K Yeoh; Andrea M Stringer; Rachel J Gibson
Journal:  Support Care Cancer       Date:  2018-05-12       Impact factor: 3.603

3.  Transforming growth factor beta-1 in rectal tumour, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients.

Authors:  Eva Angenete; Marcus Langenskiöld; Ingrid Palmgren; Peter Falk; Tom Oresland; Marie-Louise Ivarsson
Journal:  Int J Colorectal Dis       Date:  2007-07-27       Impact factor: 2.571

4.  Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.

Authors:  Magdalena Groblewska; Barbara Mroczko; Mariusz Gryko; Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz; Bogusław Kędra; Andrzej Kemona; Maciej Szmitkowski
Journal:  Tumour Biol       Date:  2014-01-07

5.  Matrix metalloproteases and TIMPs as prognostic biomarkers in breast cancer patients treated with radiotherapy: A pilot study.

Authors:  María Auxiliadora Olivares-Urbano; Carmen Griñán-Lisón; Mercedes Zurita; Rosario Del Moral; Sandra Ríos-Arrabal; Francisco Artacho-Cordón; Juan Pedro Arrebola; Amanda Rocío González; Josefa León; Juan Antonio Marchal; María Isabel Núñez
Journal:  J Cell Mol Med       Date:  2019-09-30       Impact factor: 5.310

Review 6.  Combined Radiochemotherapy: Metalloproteinases Revisited.

Authors:  Verena Waller; Martin Pruschy
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

7.  CASE REPORT Pharyngocutaneous Fistula Closure Using Autologous Fat Grafting.

Authors:  Geoffrey E Hespe; Claudia R Albornoz; Babak J Mehrara; Dennis Kraus; Evan Matros
Journal:  Eplasty       Date:  2013-05-09

8.  Microvessel density as new prognostic marker after radiotherapy in rectal cancer.

Authors:  Saulius Svagzdys; Vaiva Lesauskaite; Dainius Pavalkis; Irena Nedzelskiene; Darius Pranys; Algimantas Tamelis
Journal:  BMC Cancer       Date:  2009-03-26       Impact factor: 4.430

Review 9.  Matrix metalloproteinase-9 in relation to patients with complications after colorectal surgery: a systematic review.

Authors:  Pim Edomskis; Max R Goudberg; Cloë L Sparreboom; Anand G Menon; Albert M Wolthuis; Andre D'Hoore; Johan F Lange
Journal:  Int J Colorectal Dis       Date:  2020-08-31       Impact factor: 2.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.